Brief: Dermapharm FY Adjusted EBITDA EUR 324.8 Million
10/03/2026 06:31
Mar 10 (Reuters) - Dermapharm FY EBITDA EUR 317.6 million. FY EBITDA margin 27.3% FY adjusted EBITDA margin 27.9% FY revenue EUR 1,165 million vs. IBES estimate EUR 1,180 million
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit